Search results
Showing 1 to 5 of 5 results for etranacogene dezaparvovec
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
NICE makes 4 types of recommendation that allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice.
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
In development Reference number: GID-TA11117 Expected publication date: TBC
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.